Prosecution Insights
Last updated: May 29, 2026

Allergan, Inc.

6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
4
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (67%)
0
Easy (0%)
2
Unknown (33%)

Rejection Statute Mix

BucketCases
§103 only4 (67%)
No statute on record2 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
33% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
3
Mechanical / Eng
50% of docket
1
Business / Other
17% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
AZPURU, CARLOS A 1 83.6% +10.4%
DAVISON, LAURA L 1 32.5% +35.8%
ZIMMERMAN, REBECCA LYNEE 1 79.0% +18.9%
DUDDEN, TERESA MARIE 1 40.9% +41.7%
MEHTA, BHISMA 1 59.9% +44.0%
ISNOR, ALEXANDRA NICOLE 1 35.3% +68.8%

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18304884 IMPLANT IDENTIFICATION BY RADIOGRAPHIC MEANS ZIMMERMAN, REBECCA LYNEE 46d overdue
17789162 CROSSLINKED HA-COLLAGEN HYDROGELS AS DERMAL FILLERS ISNOR, ALEXANDRA NICOLE 16d overdue
17811217 METHODS AND APPARATUS FOR DELIVERY OF OCULAR IMPLANTS MEHTA, BHISMA 15d overdue
18015136 TISSUE EXPANSION DEVICE WITH FLUID COLLECTION DUDDEN, TERESA MARIE 4d overdue
18431278 DUAL CAP SYSTEM FOR CONTAINER-CLOSURES TO MAINTAIN TIP STERILITY DURING SHELF STORAGE DAVISON, LAURA L 22d
18599800 USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION AZPURU, CARLOS A 27d

Top Art Units

Art UnitApps
3774 2
1617 1
3993 1
3783 1
1611 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18599800 USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION AZPURU, CARLOS A 1617 Other Non-Final OA 27d Pending Mar 08, 2024
18431278 DUAL CAP SYSTEM FOR CONTAINER-CLOSURES TO MAINTAIN TIP STERILITY DURING SHELF STORAGE DAVISON, LAURA L 3993 §103 Non-Final OA 22d Pending Feb 02, 2024
18304884 IMPLANT IDENTIFICATION BY RADIOGRAPHIC MEANS ZIMMERMAN, REBECCA LYNEE 3774 §103 Non-Final OA 46d overdue Pending Apr 21, 2023
18015136 TISSUE EXPANSION DEVICE WITH FLUID COLLECTION DUDDEN, TERESA MARIE 3774 §103 Final Rejection 4d overdue Pending Jan 09, 2023
17811217 METHODS AND APPARATUS FOR DELIVERY OF OCULAR IMPLANTS MEHTA, BHISMA 3783 §103 Non-Final OA 15d overdue Pending Jul 07, 2022
17789162 CROSSLINKED HA-COLLAGEN HYDROGELS AS DERMAL FILLERS ISNOR, ALEXANDRA NICOLE 1611 Other Final Rejection 16d overdue Pending Jun 24, 2022

Managing Allergan, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month